Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
SCHAUMBURG, Ill., March 23, 2016 -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leading provider of affordable pharmaceuticals to the hospital market, announced the hiring of Sean Brynjelsen as Executive Vice President, Business Development. In this newly created role, Mr. Brynjelsen will develop and execute a strategy to drive long-term growth through the acceleration of product licensing, acquisition of products and portfolios as well as the execution of other M&A activity. Mr. Brynjelsen will report directly to Allan Oberman, Sagent’s Chief Executive Officer.
Mr. Brynjelsen joins Sagent to lead the third objective of our “Triple E” growth strategy to execute on strategic M&A transactions to advance our growth and profitability, said Allan Oberman, chief executive officer of Sagent. “Sean has extensive experience in pharmaceutical transactions, strategic planning and product licensing/development, which makes him a great addition to our executive leadership team. This newly created position, in conjunction with the addition of our EVP of Global Operations earlier this quarter, fulfills our commitment to strengthen the leadership of Sagent and support the acceleration of our ability to execute on our growth strategy.”
Mr. Brynjelsen has over 20 years of transactional experience in the pharmaceutical industry with companies including Akorn, Hospira and Baxter. Most recently, he served as Senior Vice President, Global Business Development for Akorn where he completed over one hundred transactions including the acquisition of over 25 products contributing greater than $300 million of annual revenue. He earned an MBA degree from the University of Notre Dame and holds a Master of Science in Chemistry and a Bachelor of Science in BioChemistry from the University of Illinois.
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc., founded in 2006, is a leading provider of affordable pharmaceuticals to the hospital market. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605
